Juno Therapeutics soared in its Nasdaq debut Friday, after pricing above its expected range. CEO Hans Bishop told CNBC he thinks investors are generally optimistic about immunotherapy, as well as the biopharmaceutical company's cancer treatments in development.
"I think there's a recognition that we are making real progress towards potential breakthroughs that could offer new hope to these patients battling the disease," Bishop said in an interview with "Squawk on the Street."
Juno rose as much as 64.5 percent in its market debut, valuing the company at about $3 billion.
It priced its 11 million shares at $24, above the expected range of $21 to $23. The initial public offering raised $264.5 million.